Therapy News and Research

RSS

MH6 vaccine shows promise in treating meth addiction

Scientists at The Scripps Research Institute (TSRI) have performed successful tests of an experimental methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication.

2 Nov 2012

Insomnia and sleep apnoea turn us into major health service consumers

Insomnia and sleep apnoea are turning us into major health service consumers, causing us to be less productive at work, and may even lead to serious accidents.

2 Nov 2012

Roundup: Texas will keep Planned Parenthood Women's Health Program for now; Kids' autism covered in Wash. Medicaid; UnitedHealth selling S.C. Medicaid biz

Planned Parenthood will continue to receive funds from a joint Texas and federal program providing health care to low-income women, despite the state's promise to exclude its clinics by Nov. 1 because they are affiliated with abortion providers.

2 Nov 2012

FDA clears Accuray’s new CyberKnife M6 Series

Accuray Incorporated, the premier radiation oncology company, today announced that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new CyberKnife M6 Series.

2 Nov 2012

FoXTROT results: preoperative chemo could become new standard

Preoperative chemotherapy is a feasible option for resectable advanced colon cancer, show results of the FoXTROT trial.

1 Nov 2012

Genetic underpinning of placebo effect identified

US researchers have identified a gene that appears to be responsible for the placebo effect.

1 Nov 2012

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

A drug which was originally developed to treat leukaemia and other cancers of the immune system offers substantial improvements over existing treatments in reducing relapse rates for people with multiple sclerosis (MS), even when they have not responded well to first-line treatment, according to the results of two phase 3 trials published Online First in The Lancet.

1 Nov 2012

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012.

1 Nov 2012

Blocking hyaluronidase activity can help repair brain damage associated with MS

Researchers at Oregon Health & Science University have discovered that blocking a certain enzyme in the brain can help repair the brain damage associated with multiple sclerosis and a range of other neurological disorders.

1 Nov 2012

CSHL scientists discover new way to specifically target and kill cancer cells

Cancer cells grow fast. That's an essential characteristic of what makes them cancer cells. They've crashed through all the cell-cycle checkpoints and are continuously growing and dividing, far outstripping our normal cells. To do this they need to speed up their metabolism.

1 Nov 2012

Nisin may slow or prevent squamous cell head and neck cancers

Nisin, a common food preservative, may slow or stop squamous cell head and neck cancers, a University of Michigan study found.

1 Nov 2012

Clinical hypnosis can effectively reduce hot flashes among postmenopausal women

Clinical hypnosis can effectively reduce hot flashes and associated symptoms among postmenopausal women, according to a new study conducted by researchers at Baylor University's Mind-Body Medicine Research Laboratory.

1 Nov 2012

Study shows increased risk of local recurrence in women with triple negative breast cancer

Research from The Cancer Institute of New Jersey (CINJ) shows that women with triple-negative breast cancer and no more than three positive lymph nodes following a mastectomy have a higher risk of local recurrence than similar women whose disease is not classified as triple-negative.

1 Nov 2012

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.

1 Nov 2012

Encouraging results from stereotactic radiosurgery Phase I trial on kidney cancer

A first-of-its-kind clinical trial conducted at University Hospitals (UH) Case Medical Center Seidman Cancer Center has shown encouraging results for the use of stereotactic radiosurgery to treat kidney cancer.

1 Nov 2012

Exosomes alone could protect infants' lungs from dangerous inflammation

Researchers at Boston Children's Hospital have found that microscopic particles containing proteins and nucleic acids called exosomes could potentially protect the fragile lungs of premature babies from serious lung diseases and chronic lung injury caused by inflammation.

1 Nov 2012

Single dose of etanercept can improve chronic neurological dysfunction from stroke or TBI

A new ground-breaking study about to be published in the Adis journal CNS Drugs provides clinical evidence that, for the first time, chronic neurological dysfunction from stroke or traumatic brain injury can rapidly improve following a single dose of a drug that targets brain inflammation, even years after the stroke or traumatic event.

1 Nov 2012

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

New index can help clinicians assess patients' prosthetic arm progress

Amputees with a new prosthetic arm must learn how to use their device to perform everyday tasks that were once second nature. Taking off a shirt becomes a conscious, multistep effort: grasp the shirt, lift the shirt over the head, pull arms through the sleeves, place the shirt on the table, let go of the shirt.

1 Nov 2012

Varian highlights numerous lung cancer treatment systems at ASTRO meeting

Varian Medical Systems highlighted the company's technologies for the non-invasive treatment of lung cancer at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston this week.

1 Nov 2012